Small Cell Lung Cancer Clinical Trials (April 2026): Find SCLC Trials

Last updated: April 19, 2026

Current Clinical Trial Landscape

Recruiting Trials by Treatment Setting

Limited-Stage SCLC

Chemoradiation is standard. Trials test immunotherapy additions and adjuvant strategies:

• Consolidation/adjuvant immunotherapy:
  • NCT06117774 - Tarlatamab after chemoradiation in limited-stage SCLC (Phase 3)
  • NCT04267848 - Immunotherapy added to usual chemo+RT for LS-SCLC (Phase 3)
  • NCT04402788 - RT added to atezolizumab maintenance after chemo in LS-SCLC (Phase 3)
• Adjuvant after surgery:
  • NCT06498635 - Immunotherapy after surgery for pathologic CR in SCLC (Phase 3)
  • NCT06931717 - Adjuvant cemiplimab after surgery for SCLC (Phase 3)

Extensive-Stage SCLC — First-Line

Platinum/etoposide + IO is standard. Trials test new combos and additions:

• Tarlatamab combinations:
  • NCT07005128 - Tarlatamab + durvalumab + carboplatin + etoposide vs durvalumab + carbo/etop (Phase 3)
• Novel IO combinations:
  • NCT06712316 - BNT327 + chemo + atezolizumab or durvalumab for ES-SCLC (Phase 3)
  • NCT06312137 - Pembrolizumab ± sacituzumab tirumotecan (ADC) for ES-SCLC (Phase 3)
  • NCT06096844 - Chemo + IO vs IO alone for older adults with ES-SCLC (Phase 3)

Extensive-Stage — Second-Line and Beyond

After first-line failure, tarlatamab and lurbinectedin are established. Novel DLL3-targeted agents and ADCs are in trials:

• DLL3-targeting:
  • NCT07005102 - Telisotuzumab vedotin (DLL3 ADC) for previously treated SCLC (Phase 3)
• Other novel agents:
  • NCT06452277 - Sevabertinib vs topotecan in previously treated SCLC (Phase 3)
  • NCT06745908 - N-803 + tislelizumab + docetaxel vs docetaxel alone (Phase 3)

Brain Metastases

Brain mets are common in SCLC. Trials testing focused approaches:

• • NCT05317858 - Blood-brain barrier opening using focused ultrasound + standard treatment (Phase 3)

Showing selected notable trials. View all recruiting SCLC interventional trials on ClinicalTrials.gov.

Frequently Asked Questions